HIMS Stock Just Did Something Wall Street Wasn’t Ready For

When a mid-cap telehealth company becomes the most talked-about ticker on the street for a week in a row, it can lead to a certain kind of madness. In mid-April 2026, Hims & Hers Health effectively accomplished that. Over the course of five sessions, shares increased by almost 49%, including an 11% one-day spike on Monday that made even seasoned traders grab their calculators. Then, Tuesday came almost exactly on schedule, and Amazon entered.

It’s like watching someone run up a flight of stairs only to encounter another set of stairs at the top when you watch this stock develop over the last few months. It is not insignificant that the company recovered more than 125% from its lowest point in February. Catalysts are needed for that kind of recovery; it doesn’t just happen. In Hims’ case, two came almost at the same time: a handshake with the company that had been suing them and a regulatory signal from Washington.

Hims & Hers Health, Inc.

It’s easy to underestimate the potential significance of the regulatory piece, which is genuinely fascinating. Health Secretary Robert F. Kennedy Jr. declared on April 15 that the FDA will hold a meeting in July to review restrictions on 12 peptides that were added to a restricted list during the Biden administration in 2023. Kennedy described the possible policy reversal as “overdue action,” mentioning that he personally uses peptide therapies during an appearance on the Joe Rogan podcast. You are free to discuss the politics of that. The fact that Hims purchased a peptide manufacturing facility in California back in February 2025 is more difficult to dispute. They anticipated this, or at the very least, set themselves up for it. Whether deliberate or fortunate, this type of planning often affects stock prices.

The Novo Nordisk situation is another. Compounded semaglutide was the subject of legal disputes between Hims and the Danish pharmaceutical giant; in essence, Hims was providing less expensive compounded versions of weight-loss medications that Novo preferred that patients purchase directly from them. The two businesses settled. Additionally, Hims can now sell Wegovy-branded goods on its telehealth platform thanks to the new agreement. That’s a business improvement as well as a legal victory. The brand-name medication will now be available to patients who visit Hims in search of a weight-loss solution without ever leaving the platform. If the execution is correct, there is a true business logic to this.

However, whether the Novo partnership will result in the kind of margin improvement Hims needs to support its valuation is still up in the air. With a P/E ratio of about 57, the stock was trading at about $29 on Tuesday, down more than 5% for the day. This is not cheap for a company that analysts still predict will see a 70% year-over-year decline in earnings per share when first-quarter results are released on May 11. That’s what aggressive capital investments typically do. Whether those investments eventually pay off or if they are merely expenditures that make the balance sheet appear more strained than the growth story justifies is the question.

Amazon is the specific cause of the Tuesday selloff. Amazon One Medical, a comprehensive GLP-1 Management Program that unifies primary care, pharmacy services, and virtual care under one roof, was announced by the e-commerce and cloud giant. Wegovy, Zepbound, and Foundayo are among the injectable and oral GLP-1 drugs available on the platform; insurance-backed prices start at $25 per month, while cash-pay options start at $149. Delivery is offered all over the country, and almost 3,000 locations offer same-day service. For background, this type of seamless access is the foundation of Hims’ telehealth model. The same product, constructed on an unfathomably larger scale, was just described by Amazon.

On the same news, LifeMD fell more than 10%. Hims dropped by more than 5%. It’s difficult to ignore how quickly sentiment changed: one day, there was a 49% increase due to regulatory optimism and a pharmaceutical partnership, and the next, there was a reminder that the world’s most resource-rich company had just determined your market was intriguing. Through its coupon program, Amazon’s pharmacy customers have already saved over $200 million. In addition to being a marketing line, that number has a warning attached to it.

Hims is not without its cards, though. The infrastructure of the California peptide manufacturing facility is truly unique. For 2026, the company has already revealed a “longevity specialty” product line that includes GLP therapeutic options, peptides, and coenzymes. Over the past five years, earnings growth has averaged 65.6% per year. Additionally, the stock may be trading at about 49% below its estimated intrinsic value, according to some analysts using discounted cash flow models. However, this kind of estimate should be treated with the same healthy skepticism as any other spreadsheet-based projection.

The market for GLP-1 is huge and continues to expand. Every major player, including Eli Lilly, Novo Nordisk, and now Amazon, wants a piece of the action as obesity treatment has transitioned from specialty medicine to mainstream consumer health. Because it made the process simpler, quicker, and less expensive for people who didn’t want to go to a traditional doctor’s office for a prescription they’d seen advertised on Instagram, Hims carved out early space in this market. That was a really wise realization. The question that will likely define the next 18 months of HIMS stock is whether it turns into a sustainable business advantage or just a first-mover advantage that bigger competitors eventually absorb.

The Amazon announcement might be just one negative day in a longer tale of recovery. It might also be a sneak peek at how challenging this area is going to get. This particular stock feels less like a simple wager and more like a referendum on how telehealth actually scales in a world where the biggest players are paying attention because both things can be true at the same time.